Joint (NASDAQ: JYNT) and Diplomat Pharmacy (NYSE:DPLO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk.
Volatility & Risk
Joint has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Comparatively, Diplomat Pharmacy has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500.
This is a summary of current recommendations for Joint and Diplomat Pharmacy, as reported by MarketBeat.com.
||Strong Buy Ratings
Joint presently has a consensus target price of $6.15, suggesting a potential upside of 24.49%. Diplomat Pharmacy has a consensus target price of $20.31, suggesting a potential downside of 11.65%. Given Joint’s stronger consensus rating and higher possible upside, analysts plainly believe Joint is more favorable than Diplomat Pharmacy.
Earnings & Valuation
This table compares Joint and Diplomat Pharmacy’s revenue, earnings per share and valuation.
||Earnings Per Share
Diplomat Pharmacy has higher revenue and earnings than Joint. Joint is trading at a lower price-to-earnings ratio than Diplomat Pharmacy, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
45.2% of Joint shares are owned by institutional investors. Comparatively, 72.2% of Diplomat Pharmacy shares are owned by institutional investors. 6.1% of Joint shares are owned by company insiders. Comparatively, 30.2% of Diplomat Pharmacy shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This table compares Joint and Diplomat Pharmacy’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Diplomat Pharmacy beats Joint on 9 of the 13 factors compared between the two stocks.
The Joint Corp. develops, owns, operates, supports and manages chiropractic clinics through direct ownership, management arrangements, franchising and the sale of regional developer rights throughout the United States. The Company is franchisor and operator of chiropractic clinics. The Company offers its patients the opportunity to visit its clinics without an appointment and receive prompt attention. The Company has approximately 310 franchised, company-owned, or managed clinics in operation in over 30 states. In addition to its approximately 310 operating clinics, the Company has granted franchises either directly or through its regional developers for an additional over 170 clinics. The Company offers a range of membership and wellness packages. Each patient’s records are digitally updated for ready retrieval in its data storage system by its chiropractors in compliance with various applicable medical records security and privacy regulations.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc. (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions. The Company provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups, hospitals and health systems. The Company offers various services, such as specialty drug dispensing, retail specialty services, hospital and health system services, and hub services. The Company’s patient care system is used to coordinate and track patient adherence and safety.
Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.